Clinical Trial Update: Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating CART-19/BCMA CAR-T cells targeting CD19 and BCMA in high-risk multiple myeloma patients following autologous stem cell transplant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CART-19/BCMA

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Safety and Efficacy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING